automatic hemoglobin analyzer / pediatric / bench-top
Trinity Biotech plc.
GeneSys™ Newborn Screening platform is the first on the market to offer a fully automated approach for newborn screening while providing presumptive identification for all key infant haemoglobin variants.
Newborn screening for inborn errors of metabolism offers the potential of substantially altering the natural history of these diseases by reducing morbidity and mortality. Neonatal identification of sickle cell disease can significantly reduce mortality and morbidity during the first 5 years of life. High performance liquid chromatographic methods with high sensitivity and specificity have been developed for haemoglobin fractionation. The HPLC screening method quantifies the relative concentrations of haemoglobin variants and has a good reproducibility with singleton determination.
Trinity Biotech,a leader in HPLC haemoglobin variant testing, now brings its expertise to Newborn Screening. GeneSys™ system is designed for high volume throughput and ease of use. The established reliability of the instrument adds efficiency, reduces costs and sets the industry standard for haemoglobin variant testing.